drugset / Trial / NCT06461039

A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant

NCT06461039

Phase 1 Completed 43 enrolled Novo Nordisk A/S
NaSequentialOpen-labelTreatment

Summary

This study medicine NNC0487-0111 to improve the treatment options for people living with overweight and obesity or with type 2 diabetes. The purpose of the study is to investigate if NNC0487-0111 affects how effective birth control pills are. Participants will take 1-tablet once daily. The study medicine will taken orally for 18 weeks and then study medicine will be injected with a thin needle in a skin fold in the abdomen for 9 weeks.The study will last for about 35 weeks.

Timeline

Start
2024-06-14
Primary completion
2025-03-16
Completion
2025-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule 150 ug Oral
Subject NNC0487-0111 Unknown Subcutaneous
Subject ethinyl estradiol Small molecule 30 ug Oral
Background Acetaminophen Small molecule 500 mg Oral

Indications